SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Wockhardt receives USFDA's tentative approval for Duloxetine hydrochloride

08 Jul 2011 Evaluate

Pharmaceuticals and biotechnology major Wockhardt has received tentative approval from the United States Food & Drug Administration (USFDA) for marketing 20 mg, 30 mg and 60 mg delayed release capsules of Duloxetine hydrochloride which is used in the treatment of depression.

Duloxetine is the generic name for the brand Cymbalta marketed in the United States by Eli Lilly and Company. The patent covering is under litigation in the US courts and the company will launch the product after resolution of the same. According to IMS Health, the total market for this product in US is about $3.3 billion.

Duloxetine is amongst the most widely used drug in treating depression and generalized anxiety disorders. The company would be manufacturing Duloxetine HCI API at its FDA approved facility in Ankleshwar, Gujarat and the capsules at its facility in Aurangabad. Further, the technology for the API as well as for the delayed release capsules was developed in house.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s , the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1405.40 8.60 (0.62%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×